

Qty: 100 μg/400 μl Rabbit anti-Smad2 **Catalog No.** 51-1300 **Lot No.** See product label

Rabbit anti-Smad2

FORM

This polyclonal antibody is supplied as a 400 μ l aliquot at 0.25 mg/ml in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide (NaN₃). The antibody is epitope affinity-purified from rabbit antiserum.

POLYCLONAL ANTIBODY DESIGNATION (PAD): MHA2

IMMUNOGEN

A 27 amino acid synthetic peptide derived from the MH1 domain of human Smad2. This peptide shares 24/27 residues with the mouse Smad2 protein and 26/27 residues with the *Xenopus* Smad2 protein.

SPECIFICITY

This antibody is specific for Smad2 and can be used to detect the predominant splice form of Smad2. Cross-reactivity with Smad3 or with other Smad family members has not been observed. Antibody reactivity was confirmed by Western blotting using lysates derived from Smad2-transfected COS cells and Jurkat cell lysates.

REACTIVITY

This antibody reacts with human Smad2. Reactivity with other species has not been tested.

Sample	Western Blotting	ELISA
Human	+++	
Immunogen		+++

USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. We recommend the following ranges as starting points for this product.

ELISA: 0.1-1.0 μg/ml Western Blotting⁽¹⁰⁾: 1-3 μg/ml

STORAGE

PI511300

Store at 2-8°C for up to one month. Store at -20°C for long term storage. Avoid repeated freezing and thawing.

BACKGROUND

Signaling events leading to transcriptional activation initiated by members of the TGF-beta superfamily are known to be mediated by SMAD proteins. Biological activities mediated by SMADs include cell growth and morphogenesis, development, and immune response. Activation by TGF- β is mediated by Smad2 and Smad3 while activation by bone morphogenetic protein (BMP) is mediated by Smad 1 and Smad 5. In contrast to the activating effects of these Smad proteins, Smad6 and Smad7, whose expression is also induced by ligand binding, appear to function as negative regulators of TGF- β superfamily signaling pathways.

(cont'd)

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, <u>www.invitrogen.com</u>). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

REFERENCES

- Casellas R. and Brivanlou A.H., Xenopus Smad7 inhibits both the activin and BMP pathways and acts as a neural inducer. 1 Developmental Biology, 1998 Jun 1, 198(1):1-12.
- 2. Takase M, Imamura T, Sampath TK, Takeda K, Ichijo H, Miyazono K, Kawabata M. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochemical and Biophysical Research Communications, 1998 Mar 6, 244(1):26-9.
- 3. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. *Genes and Development*, 1998 Jan 15, 12(2):186-97. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K. Smad6 inhibits signalling by the TGF-beta superfamily
- 4. [see comments]. Nature, 1997 Oct 9, 389(6651):622-6.
- Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, et al. Identification 5. of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling [see comments]. Nature, 1997 Oct 9, 389(6651):631-5.
- Topper JN, Cai J, Qiu Y, Anderson KR, Xu YY, Deeds JD, Feeley R, Gimeno CJ, Woolf EA, Tayber O, et al. Vascular MADs: two novel 6. MAD-related genes selectively inducible by flow in human vascular endothelium. PNAS, 1997 Aug 19, 94(17):9314-9.
- 7. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Research, 1997 Jul 1, 57(13):2578-80.
- Massague, J., Annu. Rev. Biochem. 67:753-791 (1998). Review 8.
- Hata, A., et al., Mol. Med. Today 4:257-62 (1998). Review 9
- 10. Ulloa, L., et al; Nature 397: 710-713 (1999).

Conjugate	Cat. No.
Sepharose 4B	10-1041
Sepharose 4B	10-1241
Unconjugated	81-6100
Unconjugated	81-6500
	<i>Conjugate</i> Sepharose 4B Sepharose 4B Unconjugated Unconjugated

Secondary antibody conjugates.

Conjugate	Goat anti-rabbit lgG (H+L)	Goat anti-mouse lgG (H+L)	Ex/Em*	Fluorescence similar to
Alexa Fluor® 488	A11008	A11001	495/519	FITC
Alexa Fluor® 555	A21428	A21422	555/565	Cy3
Alexa Fluor® 594	A11012	A11005	590/617	Texas Red
Alexa Fluor® 647	A21244	A21235	650/668	Cy5
HRP	81-6120	81-6520	NA**	NA
AP	81-6122	81-6522	NA	NA
Biotin	B2770	B2763	NA	NA

*Excitation/emission (nm); **Not applicable

For additional secondary antibody conjugates, visit www.invitrogen.com/antibodies

For Research Use Only

SS000928

(Rev 10/08) DCC-08-1089

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.